<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2065">
  <stage>Registered</stage>
  <submitdate>6/08/2008</submitdate>
  <approvaldate>6/08/2008</approvaldate>
  <nctid>NCT00730288</nctid>
  <trial_identification>
    <studytitle>Study of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects</studytitle>
    <scientifictitle>Safety of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CYD10</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dengue</healthcondition>
    <healthcondition>Dengue Fever</healthcondition>
    <healthcondition>Dengue Hemorrhagic Fever</healthcondition>
    <healthcondition>Dengue Virus</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Chimeric dengue serotype (1, 2, 3, 4)
Other interventions - Chimeric dengue serotype (1, 2, 3, 4)
Other interventions - Chimeric dengue serotype (1, 2, 3, 4)

Experimental: 1 - Received monovalent Vero dengue vaccine in Study DIV12

Experimental: 2 - Received Yellow fever vaccine in Study DIV12

Experimental: 3 - Flavivirus-naive subjects


Other interventions: Chimeric dengue serotype (1, 2, 3, 4)
0.5 mL, Subcutaneous, 1 dose

Other interventions: Chimeric dengue serotype (1, 2, 3, 4)
0.5 mL, Subcutaneous, 1 dose

Other interventions: Chimeric dengue serotype (1, 2, 3, 4)
0.5mL, Subcutaneous, 1 dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Immunogenicity: To provide information concerning the immunogenicity of ChimeriVax</outcome>
      <timepoint>28, 60 and 180 days post vaccination</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety: To provide information concerning the safety of ChimeriVax</outcome>
      <timepoint>28 days post-vaccination and entire study duration</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria :

          -  Aged 18 to 40 years on the day of inclusion.

          -  Informed consent form signed.

          -  For a woman, inability to bear a child or negative serum pregnancy test.

          -  Completed the one-year follow-up of Study DIV12.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  For a woman of child-bearing potential: use of an effective method of contraception or
             abstinence for at least four weeks prior to vaccination and at least four weeks after
             vaccination.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria :

          -  History of thymic pathology (thymoma), thymectomy, or myasthenia gravis.

          -  Breast-feeding.

          -  Systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or a vaccine containing the same
             substances.

          -  Previous flavivirus vaccination, e.g. Japanese encephalitis or yellow fever.

          -  Current abuse of alcohol or drug addiction that may interfere with the subject's
             ability to comply with trial procedures.

          -  Planned participation in another clinical trial during the present trial period.

          -  History of flavivirus infection (confirmed either clinically, serologically or
             microbiologically).

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer
             chemotherapy or radiation therapy within the preceding six months, or long-term
             systemic corticosteroids therapy.

          -  Chronic illness at a stage that could interfere with trial conduct or completion.

          -  Blood or blood-derived products received in the past three months.

          -  Vaccination planned in the four weeks following the trial vaccination.

          -  Flavivirus vaccination planned during the present trial period.

          -  Planned travel during the present trial period to areas with high dengue endemicity.

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalised without his/her consent.

          -  Participation in another clinical trial in the four weeks preceding the trial
             vaccination.

          -  Any vaccination in the four weeks preceding the trial vaccination.

          -  Human Immunodeficiency Virus (HIV), Hepatitis B (Ag HBs) or Hepatitis C (HC)
             seropositivity in blood sample taken at screening.

          -  Laboratory abnormalities considered clinically significant upon the Investigator's
             judgement in blood sample taken at screening.

          -  Positive flavivirus serological test in blood sample taken at screening (for Controls
             only).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>35</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <postcode> - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the
      ChimeriVax dengue tetravalent vaccine

      Primary Objectives:

        -  To describe the safety of one injection of ChimeriVax dengue tetravalent vaccine.

        -  To describe the immune response against dengue before and after one injection of
           ChimeriVax dengue tetravalent vaccine</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00730288</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>Sanofi Pasteur Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>